Outcome on quality of life in a Canadian national sample of patients with schizophrenia and related psychotic disorders

被引:19
作者
Malla, A
Williams, R
Kopala, L
Smith, G
Talling, D
Balshaw, R
机构
[1] McGill Univ, Canada Res Chair Early Psychosis, Verdun, PQ H4H 1R3, Canada
[2] Douglas Hosp, Res Ctr, Div Clin Res, Verdun, PQ H4H 1R3, Canada
关键词
schizophrenia; quality of life; outcome;
D O I
10.1111/j.1600-0447.2006.00758.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To examine changes in subjective and objective dimensions of quality of life (QoL) in a large Canadian sample of patients with diagnosis of schizophrenia or schizoaffective disorder treated in academic and non-academic settings over a 2-year period. Method: Patients recruited in the study across the country were assessed for QoL and functioning using the Client and Provider versions of the Wisconsin Quality of Life Questionnaire (WQoL) and the Short Form-36 (SF-36) at baseline (n = 448), 1 year (n = 308-353) and 2 years (188-297). Data were analyzed to examine change across time using multivariate analyses controlling for potential influence of variables such as age, regional variation, gender, duration of illness, type of treatment taken and baseline measures of symptoms and QoL. Results: The weighted quality of life index (W-QoL-I) showed a significant change on both the client and the provider versions of the WQoL while the physical and mental composites of the SF-36 showed change only at 2 years. These changes were influenced significantly by baseline scores on W-QoL-I and in the case of provider version of the WQoL by baseline Brief Psychiatric Rating Scale (BPRS) scores. Regional variation or type of medication had no impact on improvement in QoL. Conclusion: Within a naturalistic sample of schizophrenia patients treated and followed in routine care the overall QoL showed an improvement over time but this improvement was not influenced by the type of medication prescribed.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 24 条
[1]  
Angermeyer MC, 1997, QUALITY OF LIFE IN MENTAL DISORDERS, P19
[2]  
[Anonymous], QUALITY LIFE PHARMAC
[3]   CLINICAL SERVICES RESEARCH [J].
ATTKISSON, C ;
COOK, J ;
KARNO, M ;
LEHMAN, A ;
MCGLASHAN, TH ;
MELTZER, HY ;
OCONNOR, M ;
RICHARDSON, D ;
ROSENBLATT, A ;
WELLS, K ;
WILLIAMS, J ;
HOHMANN, AA .
SCHIZOPHRENIA BULLETIN, 1992, 18 (04) :561-626
[4]   A NEW PATIENT FOCUSED INDEX FOR MEASURING QUALITY-OF-LIFE IN PERSONS WITH SEVERE AND PERSISTENT MENTAL-ILLNESS [J].
BECKER, M ;
DIAMOND, R ;
SAINFORT, F .
QUALITY OF LIFE RESEARCH, 1993, 2 (04) :239-251
[5]  
BECKER M, 1997, QUALITY LIFE MENTAL, P133
[6]  
Bobes J, 1997, QUALITY OF LIFE IN MENTAL DISORDERS, P165
[7]   Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia [J].
Browne, S ;
Roe, M ;
Lane, A ;
Gervin, M ;
Morris, M ;
Kinsella, A ;
Larkin, C ;
OCallaghan, E .
ACTA PSYCHIATRICA SCANDINAVICA, 1996, 94 (02) :118-124
[8]   Determinants of quality of life at first presentation with schizophrenia [J].
Browne, S ;
Clarke, M ;
Gervin, M ;
Waddington, JL ;
Larkin, C ;
O'Callaghan, E .
BRITISH JOURNAL OF PSYCHIATRY, 2000, 176 :173-176
[9]  
CARPENTER WT, 1981, AM J PSYCHIAT, V138, P465
[10]   MEASUREMENT OF THERAPEUTIC RESPONSE IN SCHIZOPHRENIA - A CRITICAL SURVEY [J].
COLLINS, EJ ;
HOGAN, TP ;
DESAI, H .
SCHIZOPHRENIA RESEARCH, 1991, 5 (03) :249-253